Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?

Teams from University of California San Diego and City of Hope debate whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable NSCLC.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Introduction of the UCSD vs City of Hope Face-Off

EP: 2.Advanced ALK-Rearranged NSCLC

EP: 3.Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN

EP: 4.CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC

EP: 5.Where Does the POSEIDON Regimen Fit in the NSCLC Treatment Landscape?

EP: 6.A Case of Metastatic ROS1 Fusion-Positive NSCLC

EP: 7.Patient Profile: EGFRm Post-Osimertinib

EP: 8.Patient Case: PD-L1 Negative NSCLC

EP: 9.KRAS Patient Case

EP: 10.Neoadjuvant Chemoimmunotherapy for Resectable NSCLC

Now Viewing

EP: 11.Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?

EP: 12.Treatment Options for Patients with EGFRm: EGFR TKI + Chemotherapy

EP: 13.Treatment Options for Patients with EGFRm: EGFR TKI

EP: 14.Face-Off: Award Ceremony

Recent Videos

COMMANDS and ELEMENT-MDS Trials: Long-Term Analysis, Survival, Duration of Response, and Hemoglobin Levels

Early vs Late Onset of ESA in LR-MDS: Results From Phase 3 EPO-PRETAR Trial

Clinical Scenario: TP53- Mutant AML

Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation

Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center

Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma